Adze Biotechnology Secures Bellberry HREC Approval in Australia.
Adze Biotechnology Secures Bellberry HREC Approval in Australia; First Patient Dosing Expected This Month Adze Biotechnology, Inc., a pioneering preclinical-stage company developing systemically-deliverable oncolytic immunotherapies, today announced that it has successfully obtained approval from the Bellberry Human Research Ethics Committee (HREC) in Australia for its ADZE1.